[go: up one dir, main page]

AR068057A1 - Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. - Google Patents

Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.

Info

Publication number
AR068057A1
AR068057A1 ARP080103461A ARP080103461A AR068057A1 AR 068057 A1 AR068057 A1 AR 068057A1 AR P080103461 A ARP080103461 A AR P080103461A AR P080103461 A ARP080103461 A AR P080103461A AR 068057 A1 AR068057 A1 AR 068057A1
Authority
AR
Argentina
Prior art keywords
alkyl
branched
linear
phenyl
cycloalkyl
Prior art date
Application number
ARP080103461A
Other languages
English (en)
Inventor
Maurizio Delcanale
Gabriele Armari
Elisabetta Armani
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR068057A1 publication Critical patent/AR068057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a inhibidores de la enzima fosfodiesterasa 4 (PDE4). Más en particular, se refiere a compuestos que son derivados de alcoholes de 1-fenil-2-piridinilalquilo, a métodos de preparacion de tales compuestos, a composiciones que los contienen y a su uso terapéutico. Reivindicacion 1: Un compuesto de la formula general (1) caracterizado porque Z está seleccionado del grupo que consiste en (CH2)m, en donde m = 0, 1 o 2; (CH2)nO, en donde n = 1, 2 o 3; O(CH2)p, en donde p = 0, 1, 2 o 3; CH2SO2; CHNR6; CH2NR6; NR6, en donde R6 es H o alquilo C1-4 lineal o ramificado; OCOR4R5; y CR4R5, en donde R4 está seleccionado, de modo independiente, de H o alquilo C1-4 lineal o ramificado, con preferencia metilo, opcionalmente sustituido con un cicloalquilo C1-4 y R5 está seleccionado, de modo independiente, del grupo que consiste en alquilo C1-4 lineal o ramificado, con preferencia metilo; fenilo; bencilo; NH2; y -HNCOOR', en donde R' es alquilo C1-4 lineal o ramificado, con preferencia t-butilo; R1 y R2 son diferentes o iguales y están seleccionados, de modo independiente, del grupo que consiste en H; alquilo C1-6 lineal o ramificado opcionalmente sustituido con uno o varios sustituyentes seleccionados de cicloalquilo C3-7 o cicloalquenilo C5-7; cicloalquilo C3-7; cicloalquenilo C5-7; alquenilo C2-6 lineal o ramificado; y alquinilo C2-6 lineal o ramificado; R3 es uno o varios sustituyentes seleccionados, de modo independiente, del grupo que consiste en H, CN, NO2, CF3 y átomos de halogeno; A es un sistema de anillos, es decir, un anillo mono- o bicíclico que puede estar saturado, parcialmente insaturado o insaturado, tales como arilo, cicloalquilo C3-8 o heteroarilo, en donde dicho sistema de anillos A tiene 5 a 10 átomos del anillo, en donde al menos un átomo del anillo es un heteroátomo (por ejemplo, N, S o O), en donde el sustituyente opcional Rx en el sistema de anillos A puede ser uno o varios, puede ser igual o diferente, y está seleccionado, de modo independiente, del grupo que consiste en: alquilo C1-6 lineal o ramificado opcionalmente sustituido con uno o varios cicloalquilo C3-7; alquenilo C2-6 lineal o ramificado opcionalmente sustituido con uno o varios cicloalquilo C3-7; alquinilo C2-6 lineal o ramificado opcionalmente sustituido con uno o varios cicloalquilo C3-7; cicloalquenilo C5-7; fenilo; heterocicloalquilo C3-7; OR7, en donde R7 está seleccionado del grupo que consiste en H; alquilo C1-10 opcionalmente sustituido con uno o varios cicloalquilo C3-7; cicloalquilo C3-7; alquil C1-4-heterocicloalquilo C3-7; CO alquilo C1-6; COO alquilo C1-6; fenilo; bencilo; alquil C1-10-NR8R9, en donde R8 y R9 están seleccionados, de modo independiente, del grupo que consiste en H, alquilo C1-6 lineal o ramificado y forman, con el átomo de nitrogeno al que están unidos, un anillo saturado, parcialmente saturado o insaturado, con preferencia NR8R9 está unido a alquilo C1-10 que forma, por ejemplo anillos piperidina, oxazina, imidazol saturados, parcialmente saturados o insaturados, en donde estos anillos están opcionalmente sustituidos con alquilo C1-4; y átomos de halogeno; CN; NO2; NR10R11, en donde R10 y R11 son diferentes o iguales y están seleccionados, de modo independiente, del grupo que consiste en H; alquilo C1-6 lineal o ramificado opcionalmente sustituido con fenilo o cicloalquilo C3-7; - COC6H5; CO-alquilo C1-4; COO-alquilo C1-4; CONH-alquil C1-6-R12, en donde R12 está seleccionado del grupo que consiste en H; alquilo C1-4; OR4R5; y CONH-alquil C1-4-N-alquilo C1-4; o forman, con el átomo de nitrogeno al que están unidos, un anillo saturado o parcialmente saturado, con preferencia un anillo piperidilo; alquil C1-4-NR10R11; COR12, en donde R12 es fenilo o alquilo C1-6 lineal o ramificado; oxo; HNSO2R13, en donde R13 es alquilo C1-4 o un fenilo opcionalmente sustituido con átomos de halogeno o con un grupo alquilo C1-4; SO2R14, en donde R14 es alquilo C1-4, OH o NR10R11, en donde R10 y R11 son como se definieron con anterioridad; SOR15, en donde R15 es fenilo o alquilo C1-4; SR16, en donde R16 es H, fenilo o alquilo C1-4; COOR17, en donde R17 es H, alquilo C1-4, fenilo o bencilo; y (CH2)qOR18, en donde q = 1, 2, 3 o 4 y R18 es H o cicloalquilo C1-4; y sus sales y N-oxidos farmacéuticamente aceptables en el anillo piridina.
ARP080103461A 2007-08-08 2008-08-07 Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. AR068057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114019A EP2022783A1 (en) 2007-08-08 2007-08-08 "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"

Publications (1)

Publication Number Publication Date
AR068057A1 true AR068057A1 (es) 2009-11-04

Family

ID=38754730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103461A AR068057A1 (es) 2007-08-08 2008-08-07 Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.

Country Status (38)

Country Link
US (7) US7923565B2 (es)
EP (3) EP2022783A1 (es)
JP (3) JP2010535722A (es)
KR (1) KR101200683B1 (es)
CN (1) CN101796028B (es)
AR (1) AR068057A1 (es)
AU (1) AU2008286027B2 (es)
BR (1) BRPI0814065B8 (es)
CA (1) CA2695580C (es)
CL (1) CL2008002330A1 (es)
CO (1) CO6290760A2 (es)
CY (2) CY1117324T1 (es)
DK (2) DK2185515T3 (es)
EA (1) EA017530B1 (es)
ES (2) ES2563478T3 (es)
GE (1) GEP20125537B (es)
HK (1) HK1145686A1 (es)
HR (2) HRP20160292T1 (es)
HU (2) HUE035557T2 (es)
IL (2) IL203712A (es)
JO (1) JO3181B1 (es)
LT (1) LT2947068T (es)
MA (1) MA31586B1 (es)
ME (1) ME00974B (es)
MX (1) MX2010001544A (es)
MY (1) MY152692A (es)
NO (1) NO2947068T3 (es)
NZ (1) NZ583103A (es)
PE (1) PE20090698A1 (es)
PL (2) PL2185515T3 (es)
PT (2) PT2947068T (es)
RS (2) RS54606B1 (es)
SI (2) SI2947068T1 (es)
TN (1) TN2010000044A1 (es)
TW (1) TWI444366B (es)
UA (1) UA99622C2 (es)
WO (1) WO2009018909A2 (es)
ZA (1) ZA201000832B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
PT2560611T (pt) 2010-04-21 2018-02-07 Chiesi Farm Spa Processo para proporcionar partículas com cargas eletrostáticas reduzidas
RS57061B1 (sr) * 2010-08-03 2018-06-29 Chiesi Farm Spa Formulacija suvog praha koja uključuje inhibitor fosfodiesteraze
EP3143987A1 (en) 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
PL2621494T3 (pl) 2010-09-30 2019-04-30 Chiesi Farm Spa Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji
CN106946848B (zh) * 2011-06-06 2022-01-04 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2768822B1 (en) * 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
RU2015121037A (ru) * 2012-12-05 2017-01-11 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные фенилэтилпиридина в качестве ингибиторов pde-4
CN104822669A (zh) * 2012-12-05 2015-08-05 奇斯药制品公司 作为pde-4抑制剂的苯基乙基吡啶衍生物
RU2015121043A (ru) 2012-12-05 2017-01-11 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные фенилэтилпиридина в качестве ингибиторов PDE-4
WO2014086865A1 (en) * 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
FI3587400T3 (fi) 2013-10-22 2024-06-20 Chiesi Farm Spa Menetelmä pde4:n estäjän valmistamiseksi
AR098621A1 (es) * 2013-12-05 2016-06-01 Chiesi Farm Spa Derivados de heteroarilo
CN105814034A (zh) * 2013-12-05 2016-07-27 奇斯药制品公司 用于治疗呼吸病的二苯甲基衍生物
WO2015185130A1 (en) * 2014-06-04 2015-12-10 Chiesi Farmaceutici S.P.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
EP3152203A1 (en) 2014-06-04 2017-04-12 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
US9763924B2 (en) * 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
TW201710254A (zh) * 2015-06-01 2017-03-16 吉斯藥品公司 胺基酯衍生物
MA51413A (fr) 2017-12-28 2021-04-28 Chiesi Farm Spa Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique
US11794466B2 (en) 2019-04-26 2023-10-24 Fuji Corporation Printing parameter acquisition device and printing parameter acquisition method
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
DK0652868T3 (da) * 1992-07-28 2005-02-14 Aventis Pharma Ltd Hæmmere af c-AMP-phosphodiesterase
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
ATE217611T1 (de) 1996-09-17 2002-06-15 Merck & Co Inc Verfahren zur herstellung von phosphodiesterase iv inhibitoren
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
BRPI0408223A (pt) 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
EP1634606A1 (en) * 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
US7888381B2 (en) * 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
RS57061B1 (sr) 2010-08-03 2018-06-29 Chiesi Farm Spa Formulacija suvog praha koja uključuje inhibitor fosfodiesteraze
EP3143987A1 (en) 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
CN106946848B (zh) 2011-06-06 2022-01-04 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2768822B1 (en) 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체

Also Published As

Publication number Publication date
TW200916440A (en) 2009-04-16
EP2022783A1 (en) 2009-02-11
IL203712A (en) 2016-08-31
US20120116091A1 (en) 2012-05-10
HK1145686A1 (es) 2011-04-29
TN2010000044A1 (en) 2011-09-26
SI2947068T1 (en) 2018-02-28
EA017530B1 (ru) 2013-01-30
CL2008002330A1 (es) 2009-03-20
US20150018321A1 (en) 2015-01-15
HUE035557T2 (en) 2018-05-02
MX2010001544A (es) 2010-03-15
EP2947068B1 (en) 2017-11-08
HUE027171T2 (en) 2016-10-28
MA31586B1 (fr) 2010-08-02
UA99622C2 (ru) 2012-09-10
CY1119669T1 (el) 2018-04-04
EA201000149A1 (ru) 2010-08-30
AU2008286027B2 (en) 2013-02-21
WO2009018909A2 (en) 2009-02-12
NZ583103A (en) 2012-03-30
EP2185515B1 (en) 2016-01-06
ME00974B (me) 2012-06-20
SI2185515T1 (sl) 2016-04-29
LT2947068T (lt) 2018-01-25
IL239466A0 (en) 2015-07-30
TWI444366B (zh) 2014-07-11
ES2563478T3 (es) 2016-03-15
CA2695580C (en) 2016-10-04
HRP20160292T1 (hr) 2016-04-22
CO6290760A2 (es) 2011-06-20
BRPI0814065B8 (pt) 2021-05-25
PT2947068T (pt) 2018-01-12
US7923565B2 (en) 2011-04-12
PL2185515T3 (pl) 2016-06-30
DK2947068T3 (en) 2018-01-15
US20110144070A1 (en) 2011-06-16
US8203000B2 (en) 2012-06-19
ES2655816T3 (es) 2018-02-21
JO3181B1 (ar) 2018-03-08
CN101796028A (zh) 2010-08-04
PT2185515E (pt) 2016-03-31
JP6023846B2 (ja) 2016-11-09
KR20100050501A (ko) 2010-05-13
JP2014037426A (ja) 2014-02-27
US20130137648A1 (en) 2013-05-30
DK2185515T3 (en) 2016-02-29
HRP20180212T1 (hr) 2018-03-09
BRPI0814065A2 (pt) 2015-01-06
US8383826B2 (en) 2013-02-26
US9000177B2 (en) 2015-04-07
EP2185515A2 (en) 2010-05-19
JP2010535722A (ja) 2010-11-25
AU2008286027A1 (en) 2009-02-12
JP2015163629A (ja) 2015-09-10
GEP20125537B (en) 2012-05-25
KR101200683B1 (ko) 2012-11-13
EP2947068A1 (en) 2015-11-25
BRPI0814065B1 (pt) 2020-02-11
WO2009018909A3 (en) 2009-05-14
US20110144075A1 (en) 2011-06-16
AU2008286027A2 (en) 2010-04-01
PL2947068T3 (pl) 2018-04-30
RS56765B1 (sr) 2018-04-30
CN101796028B (zh) 2013-07-10
ZA201000832B (en) 2011-04-28
NO2947068T3 (es) 2018-04-07
US9102619B2 (en) 2015-08-11
US20140135301A1 (en) 2014-05-15
PE20090698A1 (es) 2009-07-06
CY1117324T1 (el) 2017-04-26
CA2695580A1 (en) 2009-02-12
MY152692A (en) 2014-11-28
JP5746298B2 (ja) 2015-07-08
US20090048220A1 (en) 2009-02-19
RS54606B1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
AR068057A1 (es) Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio.
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
SI2751083T1 (en) Quinolone compound
AR086676A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR091023A1 (es) Inhibidores del nampt
JP2013529196A5 (es)
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
CO6210701A2 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration